These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31279576)

  • 21. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutation-specific therapies and drug repositioning in cystic fibrosis.
    Villella VR; Tosco A; Esposito S; Bona G; Raia V; Maiuri L
    Minerva Pediatr; 2019 Jun; 71(3):287-296. PubMed ID: 30761820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
    Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
    Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
    [No Abstract]   [Full Text] [Related]  

  • 24. Cystic fibrosis papers of the year 2017.
    Doull I
    Paediatr Respir Rev; 2018 Jun; 27():2-5. PubMed ID: 29627168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
    Burgener EB; Moss RB
    Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological treatment of the basic defect in cystic fibrosis.
    Roomans GM
    Cell Biol Int; 2014 Nov; 38(11):1244-6. PubMed ID: 24809326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis.
    Wang X; Liu B; Searle X; Yeung C; Bogdan A; Greszler S; Singh A; Fan Y; Swensen AM; Vortherms T; Balut C; Jia Y; Desino K; Gao W; Yong H; Tse C; Kym P
    J Med Chem; 2018 Feb; 61(4):1436-1449. PubMed ID: 29251932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view.
    De Boeck K; Lee T; Amaral M; Drevinek P; Elborn JS; Fajac I; Kerem E; Davies JC
    J Cyst Fibros; 2020 Sep; 19(5):688-695. PubMed ID: 32527602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CFTR mutations and cystic fibrosis.
    Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.
    Mickle JE; Cutting GR
    Clin Chest Med; 1998 Sep; 19(3):443-58, v. PubMed ID: 9759548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
    McPhail GL; Clancy JP
    Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Update on CFTR Drug Discovery: Opportunities and Challenges.
    D'Ursi P; Fossa P
    Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis.
    Hammond JA; Connett GJ
    Paediatr Respir Rev; 2018 Jun; 27():16-17. PubMed ID: 29914743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased mRNA and protein stability of W1282X limits response to modulator therapy.
    Aksit MA; Bowling AD; Evans TA; Joynt AT; Osorio D; Patel S; West N; Merlo C; Sosnay PR; Cutting GR; Sharma N
    J Cyst Fibros; 2019 Sep; 18(5):606-613. PubMed ID: 30803905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current insights into the role of PKA phosphorylation in CFTR channel activity and the pharmacological rescue of cystic fibrosis disease-causing mutants.
    Chin S; Hung M; Bear CE
    Cell Mol Life Sci; 2017 Jan; 74(1):57-66. PubMed ID: 27722768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of protein repair therapy in the treatment of cystic fibrosis.
    Rubenstein RC; Zeitlin PL
    Curr Opin Pediatr; 1998 Jun; 10(3):250-5. PubMed ID: 9716885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.